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Autoradiographic localization of vasopressin Via receptors in the
rat kidney using [3HJ-SR 49059
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Autoradiographic localization of vasopressin 'ia receptors in the rat
kidney using [3H]-SR 49059. Localization and characterization of binding
sites of the selective non-peptide vasopressin receptor Via ligand, [3Hj-SR
49059, were investigated in the adult rat kidney by quantitative autora-
diography using a fast-detecting radioluminographic phosphor-imaging
plate system. [3H]-SR 49059, like the other Via ligands used, showed a
total absence of binding in the papilla, discrete and sparse labeling in the
cortex and maximal binding in the outer part of the inner medulla. This
labeling seemed to be mainly associated with medullary interstitial cells
and vascular elements of the vasa recta. Conversely, [3H1-AVP intensely
labeled the V2-enriched medullo-papillary portion of the kidney and, to a
lesser extent, the cortical structures. [3H]-SR 49059 binding, quantified in
the outer part of the inner medulla in rat kidney sections, was time-
dependent, reversible, saturable and a single class of high affinity binding
sites (K = 1.48 0.16 nM) was identified. The relative potencies of the
reference peptide and non-peptide compounds to inhibit [3H]-SR 49059
binding confirm the V nature of the site and the stereospecificity of this
binding. Thus, [3H]-SR 49059 allows the mapping and characterization of
the Via receptor population present in the rat kidney. The stability and the
highly selective affinity of this non-peptide ligand for rat and human Via
receptors make it a suitable probe for the localization of Via receptors in
organs expressing heterogeneous populations of receptors.
The two neurohypophyseal hormones, vasopressin (AVP) and
oxytocin (OT), elicit a variety of biological effects in mammals
through interaction with specific receptors (Via, Vib, V2 and OT
receptors), which have now been cloned and characterized in a
large number of tissues. The Via receptor subtype mainly exists in
vascular smooth muscle cells, platelets, the liver, adrenal, uterus
and brain, whereas the Vib receptor has been initially identified in
the anterior pituitaly. The V2 receptor is present in great amounts
in the kidney and mediates the well-known antidiuretic effect of
vasopressin. Finally, oxytocin receptors are essentially located in
mammary glands, uterus and brain [1, 21.
However, most of the time, several target organs such as the
brain, kidney, and uterus express heterogeneous populations of
AVP/OT receptors [3—6]. Therefore, highly selective ligands for
each AVP/OT receptor subtype, with high stability and high
specific activity, constitute major tools for investigating the local-
ization/mapping and the pharmacological functions of each entity.
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A number of tritiated or iodinated Via peptide ligands have
been described and used to characterize AVP Via receptors in
different cell types by binding and autoradiographic analysis [2,
7—111. We recently reported a potent, non-peptide, orally-active
AVP Via receptor antagonist, SR 49059, (Fig. 1) showing selective
high affinity for both animal and human Via receptors in vitro and
in vivo [12]. Its tritiated derivative, [3H]-SR 49059, has been
synthetized and used in binding experiments as a suitable probe
for labeling and characterizing AVP Via receptors in rat and
human liver tissues [13].
The kidney predominantly expresses V2 receptors and, in small
amounts, Via and OT receptors, which are also able to control
renal function [4, 14]. More recently, polymerase chain reaction
studies revealed that Vib receptor mRNA as well are present in a
number of tissues including the kidney [15, 161. Due to the highly
selective Via profile and the strong stability of [3Hj-SR 49059, this
first non-peptide ligand appears to be a valuable probe for
discriminating between renal AVP/OT receptor subtypes and for
giving further insight into the localization of Via receptors present
in the discrete area of the kidney.
The purpose of the present work was to investigate the char-
acteristics and the distribution of the binding sites of tritiated SR
49059 in the adult rat kidney by quantitative autoradiography. A
close comparison was established with the labeling obtained in
this organ by other peptide Via ligands such as [3H]-
d(CH2)5Tyr(Me)AVP [8] and [1251]-linear AVP antagonist [7],
and by the tritiated natural hormone, [3H]-AVP.
Moreover, to overcome the drawbacks related to the use of
tritiated ligands, which provide the best spatial resolution but
require very long exposure time, a phosphor-imaging plate system
was used to allow fast detection, high sensitivity and accurate
quantification of the radioactivity bound to histological sections,
with a far wider dynamic range and greater dose-response linear-
ity than traditional radiosensitive films [17].
Methods
Materials
The non-peptide molecules, SR 49059, [(2S) 1-[(2R 3S)-(5-
chloro-3-(2-chlorophe-nyl)-1-(3,4-dimethoxybenzene-sulfonyl)-3-
hydroxy-2,3-dihydro-1 H-indole-2-carbo-nyl]-pyrrolidine-2-carbox-
amide; Fig. 11, its enantiomer (SR 49770), OPC-21268 [18] and
OPC-31260 [19] were synthesized at Sanofi Recherche (Mont-
pellier, France). All compounds were initially dissolved in DMSO
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Fig. 1. Structure of SR 49059. * indicates position of tritiation.
at a concentration of 102 M, then diluted in the appropriate test
solvent.
[3H]-SR 49059 (55 Ci/mmol) and [3H]-autoradiographic stan-
dard microscales were obtained from Amersham (Les Ulis,
France); [3H]-AVP (81 Ci/mmol) and [3H]-d(CH2)5Tyr(Me)AVP
(47 Ci/mmol) were from New England Nuclear (Les Ulis,
France); ['251]-linear AVP antagonist (phenylacetyl.D.Tyr(Me)-
Phe-Gln-Asn-Arg-Pro-Arg-Tyr-NH2; 2,000 Ci/mmol) was synthe-
sized by Dr. C, Barberis as described by Schmidt et al [7]. AVP,
OT, d(CH2)5Tyr(Me)AVP, 1-desamino-8-D-arginine (DDAVP),
(Phe2, Orn8)-Vasotocin (POVT) and [Deamino-Cys1 ,D-3-(Pyri-
dyl)-A1a2,Arg8]-Vasopressine (d[D-3Pal]VP) were from Sigma
Chemical (L'Isle d'Abeau, France). All other chemicals were
purchased from Merck-Clevenot (Nogent sur Marne, France) or
from Prolabo (France).
Autoradiography
Young developing male Sprague-Dawley rats (20 to 30 days old,
100 g) were sacrified by decapitation and the organs (kidneys and
liver) were rapidly removed and frozen in isopentane at —45°C.
Serial sections (15 j.tm) were cut in a cryostat microtome and
thaw-mounted into gelatin chrome-alum-gelatin coated glass
slides (gelatin 1%, chrome-alum 0.05%). Sections were stored at
—80°C until use. Slide-mounted sections (3 to 4 sections/slide),
brought to room temperature, were preincubated for 15 minutes
in the binding buffer (50 nM Tris-HC1, pH 7.4, 10 mrvt MgC12, 1 mM
EGTA, 0.1% bovine serum albumin and bacitracin). Incubation
was carried out for one hour at room temperature in the
incubating medium in the presence of either [3H]-SR 49059 (0.3
to 18 nM for saturation or 1.8 to 2 nM for kinetic and competi-
tion experiments) or other ligands {[3H]-AVP (2 nM),
d(CH2)5Tyr(Me)AVP (1.8 nM) or {'251]-linear AVP antagonist
(0.02 nM)}. Non-specific binding was determined in the presence
of 1 /.LM unlabeled AVP.
After incubation, the sections were washed three times for 10
minutes each in ice-cold buffer, dipped briefly in distilled water,
and dried under a stream of cold air.
Labeled sections were placed, together with autoradiographic
standards, on a phosphor-imaging plate (Fuji) for 4 to 10 days for
tritiated and four hours for iodinated ligands. The exposed
imaging plate was scanned and the emitted stored energy quan-
tified as photo-stimulated luminescence (PSL) with a Bio-Image
* Analyser (BAS 2000, Fuji) under specific reading conditions:
gradation 1024; resolution 100; sensitivity 10,000; latitude 4. Hard
copies of the autoradiographic images were obtained using a high
quality BAS HS printer (Fuji). The PSL were collected and
* digitized to allow measurement of the relative radioactivity of the
section. The resulting 16 megabytes image exhibited a pixel size of
100 sm and the value of each pixel is expressed between 0 and
1023. Quantification of binding density was performed by calcu-
lation of the mean gradation per mm2 (PSL/mm2). Prefabricated
[3H]-labeled polymer strips (0.03 to 32.4 nCi/mg tissue equivalent,
Amersham, microscale) were used to convert intensities into
fmol/mg tissue equivalent [20].
Binding data analysis
The IC50 value was defined as the concentration of inhibitor
required to obtain 50% inhibition of the specific binding. The
inhibition constant (K1) values were calculated from IC50 values
using the Cheng and Prusoff equation [211. Data for equilibrium
binding (Kd, Bmax), competition experiments (IC50, H) and
kinetic constants (KObS, K1) were analyzed using an iterative
non-linear regression program [22]. Results were expressed as
means SD.
Results
Quantitative autoradiographic analysis by the imaging plate system
The autoradiographic technique provides quantitative data
because the film intensities observed are proportional to the time
of exposure and tissue content of radioactivity. In this study,
phosphor-imaging plates for sensing radioactivity energy from
tritium or iodine were used instead of tradional X-ray films. This
newly-developed radioluminographic technique has a wide linear
dynamic range as well as a high sensitivity ensuring a good
quantitative accuracy and great reduction in exposure-time (a few
days instead of months in our case) [17, 23—251. On the other
hand, the resolution of imaging plates is, in general, less than that
of X-ray films due to the characteristics of the image reader. As
shown in Figure 2, using [3H]-labeled autoradiographic standards
as references, the imaging plate response is perfectly linear
between 0.03 to 32.4 nCi/mg tissue equivalent and detection is
proportionnal over exposure-time (r2> 0.99; not shown).
Autoradiographic distribution of AVPbinding sites in Sprague-
Dawley rat kidney sections
As expected, [3H]-AVP intensely labeled the medullo-papillary
portion of the kidney and, to a lesser extent, the cortical structure
corresponding to V2 and Via receptors, respectively, as previously
described (Fig. 3A) [14, 26, 27].
Conversely, the non-peptide Via antagonist, [3H]-SR 49059
(Fig. 3B) and the other selective peptide Via ligands used,
[3Hj.d(CH2)5Tyr(Me)AVP (Fig. 3C) and ['251]-linear AVP antag-
onist (Fig. 3D), showed an absence of binding in the papillary area
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Fig. 2. Quantitative analysis of radioactive standards using the imaging plate
system. [3H]-autoradiographic standards (dose-ranging: 0.03 to 32.4
nCi/mg tissue equivalent) were apposed 2 (LI), 5 (0), 8 (•) and 10 ()
days to the phosphor-imaging plate. Inset. Dose-ranging from 0.03 to 6
nCi/mg tissue equivalent. Density values of [3H]-labeled Amersham
standards (PSL/mm2) were analyzed at differents exposure times. The
correlation coefficient (r2) values are > 0.99 in all cases.
of the kidney, discrete labeling of the cortex and a dense and
massive labeling in the outer part of the inner medulla, probably
associated to vascular structures in this area as shown previously
by microscopic localization techniques [281. This binding spread
from the medulla to other structures in the adjacent part of the
inner stripe of the outer medulla. In this latter region the labeling
has a thin striated apparence and probably corresponds to Via
receptors localized in vasa recta [28].
It is important to note the intense labeling of the renal pelvic
wall of the papillary surface which was a remnant of capsula
fibrosa. All three Via ligands showed a similar distribution pattern
even if we obtained a higher resolution with tritiated ligands than
with the iodinated one by using the imaging plate system (Fig. 3).
Moreover, the binding observed in these autoradiograms is judged
to be specific since it was eliminated by incubating in the presence
of 1 LM cold AVP (Fig. 3, inset).
Additional control experiments were performed with {3H]-SR
49059 on rat liver sections under similar operating conditions (Fig.
3B). As expected, intense labeling was observed in all the liver in
agreement with the high level of expression of Via receptors in
this organ. Binding heterogeneity confirmed a distribution of Via
receptors to specialized hepatocytes and/or vascular epithelial
cells as previously observed on autoradiograms in this tissue using
a selective radioiodinated Via ligand [11].
Characteristics of [3H]-SR 49059 binding to slide-mounted rat
kidney sections
In these autoradiographic experiments performed in adult
Sprague-Dawley rat kidneys, we determined the properties of
[3H]-SR 49059 binding by quantification analysis of [3H]-SR
49059 labeling in the outer medulla region.
As shown in Figure 4, [3H]-SR 49059 binding to rat kidney
sections was time-dependent, reached an apparent equilibrium in
about 40 minutes, and demonstrated high stability (> 4 hours).
Thus, an incubation time of 60 minutes was chosen for the
following saturation and competition experiments. An apparent
equilibrium constant (KObS) of 0.125 0.026 minutes and a
half-maximum association time (t½) of 6 2 minutes were
calculated from these time-course binding studies. Binding of
[3H]-SR 49059 was reversible and the addition of unlabeled SR
49059 (1 M) induced rapid and full dissociation of the peptide-
receptor complex with an apparent dissociation constant (K_5)
value of 0.059 0.012 min (Fig. 4). It is worth noting that under
equilibrium conditions, non-specific binding represented 25 to
30% of total binding.
Saturation experiments of [3H}-SR 49059 binding to slide-
mounted rat kidney sections showed that the specific binding was
saturable (Fig. 5A). Scatchard analysis of data, resulting from the
labeling of [3H]-SR 49059 in the outer medulla, gave a linear plot
consistent with the presence of a single class of high affinity
binding sites with a Kd and a Bm value of 1.48 0.16 nM and 33
2 fmol/mg tissue equivalent, respectively (N = 3), A similar
analysis performed in the renal cortex yielded an equivalent Kd
value (1.05 0.25 nM) but a much lower number of binding sites
(Bm value of 4.9 0.5 fmol/mg tissue equivalent; not shown).
The binding of [3H]-SR 49059 to the outer medullary sites in rat
kidney sections was further characterized by studying the relative
potencies of several peptide and non-peptide AVP/OT agonists
and antagonists (Table 1). The receptor identified by [3H]-SR
49059 exhibited a full Via profile since d(CH2)5Tyr(Me)AVP, a
selective V1 a antagonist, showed nanomolar affinity, whereas the
specific V2 agonist, DDAVP, the non-peptide AVP V2 antagonist,
OPC-31260 [19], oxytocin and d[D-3Pal]VP, described as a selec-
tive Vib agonist [29], were much less potent (IC50 values > 200
nM).
As shown in Figure 6, SR 49059 dose-dependently inhibited the
[3H]-SR 49059 binding to kidney slides with similar nanomolar
potency to that of d(CH2)5Tyr(Me)AVP. Conversely, the other
non-peptide Via compound, OPC-21268 exhibited a 100-fold
lower affinity, in agreement with that previously reported for Via
receptors in rat liver membranes [18]. Furthermore, [3H]-SR
49059 binding to renal Via receptors was highly stereospecific
since SR 49059's enantiomer, SR 49770, had 50-fold less affinity
than SR 49059 (Table 1; Fig. 6). These data are consistent with
previous results obtained with SR 49059 and SR 49770 in different
cell types expressing Via receptors such as Swiss 3T3 fibroblasts,
human vascular smooth muscle cells, and rat and human liver [13,
30, 311. In all cases, dose-response curves for these compounds
gave a linear Hill plot and pseudo Hill coefficients (nH) about
unity indicating competitive antagonism with the ligand. More-
over, K and Kd values for SR 49059, calculated from kinetic,
saturation or competition experiments [21, 22] by analysis of the
different autoradiograms were highly similar (1, 1.48 and 1.25 ni,
respectively).
Discussion
The present study demonstrates that [3H]-SR 49059, which is
the first tritium-labeled non-peptide vasopressin receptor Via
ligand yet described, is a suitable probe for investigating the
distribution of Via receptors in complex tissues such as the kidney
expressing a low density of Via sites together with mixed popula-
tions of AVP/OT receptor subtypes.
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Fig. 3. Localization of vasopressin binding sites in rat kidney and liver tissue sections. [3H1-AVP (A), [3H1-SR 49059 (B), [3H1-d(CH2)5Tyr(Me)AVP (C),
and ['251J-linear AVP antagonist (D) labeling in Sprague-Dawley rat autoradiograms. Inset. Non-specific binding obtained for each ligand by incubating
in the presence of 1 zM unlabeled AVP. Graduation color bar: lower higher intensity of labeling.
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Fig. 4. Time-course of association (•) and dissociation (0) of [3H1-SR
49059 to slide-mounted rat kidney sections. Incubations were carried out as
described in the text in the presence of [3H1-SR 49059 (1.9 nM) for various
periods of time. Arrow indicated time (60 mm) at which cold SR 49059 (1
was added to initiate the dissociation process. Results represent data
from a typical experiment performed in triplicate.
In spite of these difficulties, the complete characterization of
the site labeled by [3H]-SR 49059 was achieved in slide-mounted
adult rat kidney sections by receptor autoradiography using, for
the first time, a phosphor-imaging plate detecting system. In the
present case, this method was of high interest in order to benefit
from the best spatial resolution provided by tritiated ligands and
to avoid the very long exposure-times with traditional photo-
graphic emulsions. Therefore, using the selective AVP Via ligand,
[3H]-SR 49059, together with highly sensitive and faster autora-
diographic phosphor-screens (10 to 100 times more than X-ray
films), it took on average a four day-exposure, instead of months,
in order to obtain the full mapping of AVP Via receptors in
discrete areas of rat kidneys. The wide dynamic range and the
linear response obtained with extremely strong signals on radio-
luminographic plates allowed accurate quantification, even in
sections with both low and intense labeling (that is, saturation
experiments on tissue sections, whole body autoradiography [23—
251). This expanding methodology has been recently successfully
applied to detecting the complex distribution of neuropeptide
receptors such as cholecystokinin binding sites in rat brain [32] or
endothelin receptors in human microvessels [331.
Considering the Via receptor distribution in (20 to 30 days-old)
rat kidneys, [3HJ-SR 49059 and other peptide Via ligands used
{[3H]-d(CH2)5Tyr(Me)AVP and ['251]-linear AVP antagonist} [7,
8] provided a similar labeling pattern expressed in three main
regions: a large and dense band in the outer part of the inner
medulla, radiating streaks in the inner part of the outer stripe of
the medulla and sparse and low labeling of the cortex. Whatever
the Via ligand used, no radioactivity was detected in the papilla.
Conversely, [3H]-AVP intensely labeled this latter V2 receptor-
enriched medullo-papillary region correlating with the AVP re-
ceptor distribution reported by others [14, 26, 27].
Full characterization of [3H]-SR 49059 binding sites, by quan-
tification analysis in the intensely labeled outer part of the inner
medulla region, confirmed the Via nature of the site identified.
Binding of [3H1-SR 49059 to rat kidney sections was time-
dependent, reversible, saturable and exhibited similar properties
to those already described for liver Via receptors in rat and
human tissues [13]: a single high affinity binding site (Kd = 1.48
0.16 nM), high binding stability, rapid dissociation of the receptor-
ligand complex (t½ = 5 mm) and stereospecificity. The relative
potencies of reference peptide and non-peptide compounds in
inhibiting [3H]-SR 49059 binding showed that the binding site
identified by [3H]-SR 49059 exhibited a fully Via profile: AVP
d(CH2)5Tyr(Me)AVP SR 49059 << oxytocin or DDAVP or
d[D-3Pal]VP or OPC-31260. Moreover, the high selectivity profile
previously described for SR 49059 [121 was of particular interest in
autoradiographic studies in tissues such as kidneys expressing
both AVP/OT sites (Via, V2, UT and also Vib [15, 16]) and a wide
variety of receptors for peptide or non-peptide ligands such as
endothelin, neurotensin, beta-adrenergic, neurokinin, angioten-
sin, benzodiazepin receptors.
As regards the AVP Via receptor localization in rat kidney,
although the autoradiographic technique used did not allow
localization at the cellular level, it seems reasonable to assume
that [3H]-SR 49059 binding sites are associated with medullary
interstitial cells and vascular elements of inner medulla vasa recta
and vascular bundles of outer stripe of medulla accounting for the
radiating streaks seen in the autoradiograms. Taken overall, this
pattern is consistent with the ontogenic expression of mRNA
encoding the Via receptors as reported by Ostrowski et a! in adult
Sprague-Dawley rats using in situ hybridization histochemistry, a
technique allowing microscopic localization [28, 34]. They evi-
denced the V a receptor mRNA predominantly in vascular ele-
ments adjacent to and coursing alongside collecting ducts whereas
the basic pattern of V2 mRNA expression remained in medullo-
papillary, cortical collecting ducts and moderately in the thick
ascending limbs of the ioop of Henle in the outer medulla.
Moreover, this latter study emphazises that Via receptor (and V2)
expression depends on the stage of development and more Via
receptor transcripts are detected in the developing kidney (21 to
60 days-old rats, as in the present study) than in the mature organ
(60 days-old). Besides the localization to vascular structures, an
association of Via receptors to the functional nephron segments
cannot be excluded. The reverse transcription-polymerase chain
reaction method, allowing quantification of Via and V2 mRNA in
various segments of rat Sprague-Dawley nephrons isolated by
microdissection, demonstrated consistent amounts of Via mRNA
in the cortical collecting ducts and to a lesser extent in the outer
medullary collecting duct [35]. Functional data also underline the
expression of efficient Via receptors in these segments and
physiological studies showed that specific AVP Via receptor
antagonists inhibited AVP-induced PGE2 synthesis by isolated
medullary collecting duct cells [36] and totally blocked AVP-
evoked Ca2 transients in the cortical and outer medullary
portions of the collecting ducts, consistent with a role of Via
receptors in the renal function [37]. A number of in vivo studies
support the renal role of Via receptors both at a vascular level in
regulating the renal medullary hemodynamics and the tubular
function. The direct tubular effect of Via receptor stimulation
appears to favor diuresis and/or natriuresis. Moreover, by use of
videomicroscopy, laser-Doppler fiowmetry techniques and spe-
cific Via anologues such as POVT, it is clearly demonstrated that
Via receptor stimulation in the renal medulla reduces renal
.
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Table 1. Binding affinity of several peptide and non-peptide AVP/OT
agonists and antagonists in [3H]-SR 49059 binding to Sprague-Dawley
rat kidney sections
Compounds IC50 nM
Peptide
AVP 3.50 0.11
POVT 19.53 3.12
d(CH2)5Tyr(Me)AVP 2.07 0.60
d[D-3 Pall VP 433 205
> 1000
DDAVP (24% inhibition of binding at 1 jsM)
OT 243±85
Nonpeptide
SR 49059 2.97 0.90
SR 49770 165 88
OPC-21268 435 168
OPC-31260 2360 1053
Values are means SD obtamed from 3 to 6 determinations.
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Fig. 6. Inhibition of specific /3H]-SR 49059 binding to slide-mounted rat
kidney sections by AVP (LI), d(CH2)5Tyr(Me)AVP (V), SR 49059 (U), SR
49770 (Y), OPC-21268 (•) and OPC-31260 (0). Incubations were carried
out with 1.8 nM [3Hl-SR 49059 and increasing concentrations of the test
compound for 60 minutes at room temperature. Data were means from 3
to 6 determinations.
characterization of Via receptors even in discrete area of renal
structures. The low level of non-specific binding together with
high specific-activity, stability and potent affinity for both animal
and human Via receptors [121 ensure that this non-peptide ligand
is of interest for labeling Via receptors in a variety of complex
organs expressing heterogeneous populations of AVP/OT recep-
tors.
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medullary blood flow and decreases red blood cells velocity in
descending and ascending vasa recta. In addition, chronic stimu-
lation of Via receptors could even mediate the development of
hypertension in chronically instrumented rats [38].
Since renal glomerular mesangial cells are known to possess
V10 receptors, the low labeling observed with [3H]-SR 49059
(sixfold less than in the outer part of the inner medulla according
to our quantification) and with other Via ligands in the cortex
seems an intriguing observation. In addition, the selective peptide
V0 ligand d(CH2)5Tyr(Me)AVP has shown high potency in
inhibiting both [3H]-AVP binding and AVP-induced [Ca2]1 in
cultured rat mesangial cells in vitro [39]. However, autoradio-
graphic and hybridation in situ experiments confirmed very small
amounts of V10 receptor labeling over glomeruli in the adult rat
kidney [14, 34]. Different phenotypic states between in vitro
proliferating mesangial cells and in vivo contractile cells could
explain this discrepancy. Likewise, the presence of a higher
number of mRNA V, transcripts in developing glomerular cells
than in cells at the adult stages has been described and is
consistent with the role played by V0 receptors in mediating
growth effect [34].
In conclusion, this study describes the localization and quanti-
fication of V10 receptors in adult rat kidney sections using [3H1-SR
49059 and a fast phosphor-imaging plate radioluminographic
technique. The present report points out the interest of [3H]-SR
49059 as a suitable probe for specific detection and accurate
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